vs
Amneal Pharmaceuticals, Inc.（AMRX）与CoStar Group（CSGP）财务数据对比。点击上方公司名可切换其他公司
CoStar Group的季度营收约是Amneal Pharmaceuticals, Inc.的1.2倍（$899.9M vs $722.5M），Amneal Pharmaceuticals, Inc.净利率更高（10.8% vs 5.2%，领先5.6%），CoStar Group同比增速更快（26.9% vs 3.9%），过去两年CoStar Group的营收复合增速更高（17.1% vs 1.5%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
CoStar Group是1987年成立的美国商业地产服务商，总部位于弗吉尼亚州阿灵顿，业务覆盖北美、欧洲地区，为商业地产行业提供信息、分析及营销解决方案，旗下运营CoStar线上数据库、新闻网站及Apartments.com、Homes.com等多个线上平台。
AMRX vs CSGP — 直观对比
营收规模更大
CSGP
是对方的1.2倍
$722.5M
营收增速更快
CSGP
高出23.0%
3.9%
净利率更高
AMRX
高出5.6%
5.2%
两年增速更快
CSGP
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $722.5M | $899.9M |
| 净利润 | $78.0M | $46.5M |
| 毛利率 | 44.3% | 78.6% |
| 营业利润率 | 19.6% | 5.5% |
| 净利率 | 10.8% | 5.2% |
| 营收同比 | 3.9% | 26.9% |
| 净利润同比 | 410.5% | -22.2% |
| 每股收益（稀释后） | $0.19 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXCSGP
| Q1 26 | $722.5M | — | ||
| Q4 25 | $814.3M | $899.9M | ||
| Q3 25 | $784.5M | $833.6M | ||
| Q2 25 | $724.5M | $781.3M | ||
| Q1 25 | $695.4M | $732.2M | ||
| Q4 24 | $730.5M | $709.4M | ||
| Q3 24 | $702.5M | $692.6M | ||
| Q2 24 | $701.8M | $677.8M |
净利润AMRXCSGP
| Q1 26 | $78.0M | — | ||
| Q4 25 | $35.1M | $46.5M | ||
| Q3 25 | $2.4M | $-30.9M | ||
| Q2 25 | $22.4M | $6.2M | ||
| Q1 25 | $12.2M | $-14.8M | ||
| Q4 24 | $-31.1M | $59.8M | ||
| Q3 24 | $-156.0K | $53.0M | ||
| Q2 24 | $6.0M | $19.2M |
毛利率AMRXCSGP
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | 78.6% | ||
| Q3 25 | 34.9% | 79.3% | ||
| Q2 25 | 39.5% | 78.5% | ||
| Q1 25 | 36.8% | 79.1% | ||
| Q4 24 | 36.0% | 80.1% | ||
| Q3 24 | 38.4% | 79.7% | ||
| Q2 24 | 35.6% | 80.0% |
营业利润率AMRXCSGP
| Q1 26 | 19.6% | — | ||
| Q4 25 | 13.8% | 5.5% | ||
| Q3 25 | 9.0% | -6.1% | ||
| Q2 25 | 15.4% | -3.5% | ||
| Q1 25 | 14.4% | -5.8% | ||
| Q4 24 | 10.4% | 5.6% | ||
| Q3 24 | 12.6% | 3.4% | ||
| Q2 24 | 13.6% | -2.4% |
净利率AMRXCSGP
| Q1 26 | 10.8% | — | ||
| Q4 25 | 4.3% | 5.2% | ||
| Q3 25 | 0.3% | -3.7% | ||
| Q2 25 | 3.1% | 0.8% | ||
| Q1 25 | 1.8% | -2.0% | ||
| Q4 24 | -4.3% | 8.4% | ||
| Q3 24 | -0.0% | 7.7% | ||
| Q2 24 | 0.9% | 2.8% |
每股收益（稀释后）AMRXCSGP
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | $0.12 | ||
| Q3 25 | $0.01 | $-0.07 | ||
| Q2 25 | $0.07 | $0.01 | ||
| Q1 25 | $0.04 | $-0.04 | ||
| Q4 24 | $-0.10 | $0.14 | ||
| Q3 24 | $0.00 | $0.13 | ||
| Q2 24 | $0.02 | $0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $197.7M | $1.6B |
| 总债务越低越好 | — | $140.0M |
| 股东权益账面价值 | — | $8.3B |
| 总资产 | $3.5B | $10.5B |
| 负债/权益比越低杠杆越低 | — | 0.02× |
8季度趋势，按日历期对齐
现金及短期投资AMRXCSGP
| Q1 26 | $197.7M | — | ||
| Q4 25 | $282.0M | $1.6B | ||
| Q3 25 | $201.2M | $1.9B | ||
| Q2 25 | $71.5M | $3.6B | ||
| Q1 25 | $59.2M | $3.7B | ||
| Q4 24 | $110.6M | $4.7B | ||
| Q3 24 | $74.0M | — | ||
| Q2 24 | $43.8M | — |
总债务AMRXCSGP
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | $140.0M | ||
| Q3 25 | $2.6B | $1.0B | ||
| Q2 25 | $2.2B | $1.0B | ||
| Q1 25 | $2.2B | $1.0B | ||
| Q4 24 | $2.4B | $1.0B | ||
| Q3 24 | $2.4B | $1.0B | ||
| Q2 24 | $2.4B | $1.0B |
股东权益AMRXCSGP
| Q1 26 | — | — | ||
| Q4 25 | $-70.8M | $8.3B | ||
| Q3 25 | $-109.5M | $8.6B | ||
| Q2 25 | $-112.1M | $8.6B | ||
| Q1 25 | $-131.7M | $8.6B | ||
| Q4 24 | $-109.3M | $7.6B | ||
| Q3 24 | $-93.4M | $7.5B | ||
| Q2 24 | $-57.5M | $7.4B |
总资产AMRXCSGP
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.7B | $10.5B | ||
| Q3 25 | $3.6B | $10.8B | ||
| Q2 25 | $3.4B | $10.5B | ||
| Q1 25 | $3.4B | $10.4B | ||
| Q4 24 | $3.5B | $9.3B | ||
| Q3 24 | $3.5B | $9.1B | ||
| Q2 24 | $3.5B | $9.1B |
负债/权益比AMRXCSGP
| Q1 26 | — | — | ||
| Q4 25 | — | 0.02× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $162.1M |
| 自由现金流经营现金流 - 资本支出 | — | $101.3M |
| 自由现金流率自由现金流/营收 | — | 11.3% |
| 资本支出强度资本支出/营收 | — | 6.8% |
| 现金转化率经营现金流/净利润 | — | 3.49× |
| 过去12个月自由现金流最近4个季度 | — | $123.0M |
8季度趋势，按日历期对齐
经营现金流AMRXCSGP
| Q1 26 | — | — | ||
| Q4 25 | $130.3M | $162.1M | ||
| Q3 25 | $118.5M | $68.2M | ||
| Q2 25 | $83.8M | $146.5M | ||
| Q1 25 | $7.4M | $53.2M | ||
| Q4 24 | $118.1M | $94.6M | ||
| Q3 24 | $141.8M | $100.3M | ||
| Q2 24 | $39.7M | $58.1M |
自由现金流AMRXCSGP
| Q1 26 | — | — | ||
| Q4 25 | $108.5M | $101.3M | ||
| Q3 25 | $106.2M | $-5.5M | ||
| Q2 25 | $61.0M | $27.7M | ||
| Q1 25 | $-5.8M | $-500.0K | ||
| Q4 24 | $102.9M | $25.2M | ||
| Q3 24 | $124.8M | $40.2M | ||
| Q2 24 | $29.0M | $-14.7M |
自由现金流率AMRXCSGP
| Q1 26 | — | — | ||
| Q4 25 | 13.3% | 11.3% | ||
| Q3 25 | 13.5% | -0.7% | ||
| Q2 25 | 8.4% | 3.5% | ||
| Q1 25 | -0.8% | -0.1% | ||
| Q4 24 | 14.1% | 3.6% | ||
| Q3 24 | 17.8% | 5.8% | ||
| Q2 24 | 4.1% | -2.2% |
资本支出强度AMRXCSGP
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 6.8% | ||
| Q3 25 | 1.6% | 8.8% | ||
| Q2 25 | 3.2% | 15.2% | ||
| Q1 25 | 1.9% | 7.3% | ||
| Q4 24 | 2.1% | 9.8% | ||
| Q3 24 | 2.4% | 8.7% | ||
| Q2 24 | 1.5% | 10.7% |
现金转化率AMRXCSGP
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | 3.49× | ||
| Q3 25 | 50.00× | — | ||
| Q2 25 | 3.74× | 23.63× | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | 1.58× | ||
| Q3 24 | — | 1.89× | ||
| Q2 24 | 6.62× | 3.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
暂无分部数据
CSGP
| Co Star | $503.8M | 56% |
| Other | $283.0M | 31% |
| Loop Net | $94.7M | 11% |
